Clinical experience with dual action antidepressants in different chronic pain syndromes

Human Psychopharmacology
Mike Briley

Abstract

A common psychopharmacology between pain and depression suggests that compounds inhibiting the reuptake of serotonin and/or noradrenaline are likely to produce relief from chronic pain. Indeed tricyclic antidepressants have been a standard treatment of chronic pain for many years. In spite of their improved tolerance, selective serotonin reuptake inhibitors do not appear to be particularly effective in the treatment of pain. Recently, a number of open and controlled trials with members of the new selective serotonin and noradrenaline reuptake inhibitor class of antidepressants, such as venlafaxine, milnacipran and duloxetine, suggest that these compounds may be more effective in relieving pain than selective inhibitors of serotonin reuptake. Wherever valid comparisons have been made the newer dual action drugs appear to be as effective as the tricyclics and considerably better tolerated. Dual action antidepressants are thus likely to become a widely used treatment of chronic pain both associated with and independent of depression.

References

Nov 21, 1977·JAMA : the Journal of the American Medical Association·J L DavisJ D Wallin
May 7, 1992·The New England Journal of Medicine·M B MaxR Dubner
Jan 1, 1994·Annals of Neurology·M B Max
Apr 16, 1998·Psychosomatics·M M DwightP E Keck
Jun 2, 2000·Diabetes Care·J A KiayiasE Lakka-Papadodima
Oct 13, 2000·Journal of General Internal Medicine·P G O'MalleyJ L Jackson
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
Apr 20, 2001·Clinical Pharmacology and Therapeutics·T P EnggaardS H Sindrup
May 11, 2001·The Annals of Pharmacotherapy·J E Sumpton, D E Moulin
Mar 13, 2002·European Journal of Pain : EJP·Tiina TasmuthEija Kalso
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
Sep 17, 2003·American Journal of Therapeutics·Ronald H BradleyCharles William Dodge
Oct 9, 2003·Human Psychopharmacology·Mitsuhiro KamataHisashi Higuchi
Oct 21, 2003·The Annals of Pharmacotherapy·Kemal SayarMehmet Tosun
Jan 8, 2004·Psychosomatics·David J GoldsteinMark A Demitrack
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Walker S Carlos Poston, John P Foreyt
Apr 23, 2004·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·D A FishbainR S Rosomoff
Jun 5, 2004·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Malcolm PeetC N Ramchand
Jul 15, 2004·Human Psychopharmacology·Akira Toyofuku, Haruhiko Miyako
Sep 21, 2004·Human Psychopharmacology·Olivier VittonSrinivas G Rao
Jan 1, 2003·International Journal of Psychiatry in Clinical Practice·Akira Toyofuku
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Shouhei NagaokaAkiko Sekiguchi

❮ Previous
Next ❯

Citations

Apr 26, 2006·Cellular and Molecular Neurobiology·Piotr PopikAnthony S Basile
Oct 28, 2005·The New England Journal of Medicine·J John Mann
Apr 1, 2006·Acta Neuropsychiatrica·Lana J WilliamsMichael Berk
Oct 5, 2010·PLoS Computational Biology·Raoul FrijtersWynand Alkema
Sep 3, 2011·Journal of Pain Research·Nalini VadiveluRaymond Sinatra
Nov 28, 2012·Neuropsychiatric Disease and Treatment·Yasuhide NagoshiKenji Fukui
Sep 1, 2006·Neuropsychiatric Disease and Treatment·Akira Toyofuku, Toshihiro Kikuta
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Chantal Moret, Mike Briley
Feb 1, 2007·Neuropsychiatric Disease and Treatment·Teruhiko Higuchi, Mike Briley
Jan 23, 2010·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·David R P Guay
Nov 1, 2012·Postgraduate Medical Journal·Amit PatelC Prakash Gyawali
Mar 13, 2009·Journal of Anxiety Disorders·Katja BeesdoHans-Ulrich Wittchen
Dec 6, 2006·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Gary D Klasser, Reny de Leeuw
Mar 14, 2007·Best Practice & Research. Clinical Rheumatology·Stefan Bergman
Jul 28, 2006·Journal of Psychiatric Research·Charles B Nemeroff
May 9, 2006·Gastroenterology·Ray E ClouseBruce D Naliboff
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Pedro L Delgado
May 3, 2015·Pharmacological Reports : PR·Mohammad Taghi MansouriBehnam Ghorbanzadeh
Oct 29, 2013·Clinical Therapeutics·Timothy J AtkinsonMaira Mirza
Dec 1, 2010·European Journal of Pharmacology·Kazuaki KawauraKazuo Takahama
Apr 15, 2008·The International Journal of Neuropsychopharmacology·Esther Berrocoso, Juan A Mico
Apr 25, 2013·Topics in Stroke Rehabilitation·Murray FlasterJosé Biller
Jun 10, 2006·Trends in Pharmacological Sciences·Juan A MicóAlain Eschalier
Feb 13, 2009·Expert Review of Neurotherapeutics·Susan G KornsteinSusan G Ball
Jul 9, 2011·Clinical Neuropharmacology·Yuichi KatoAkira Toyofuku
Apr 9, 2009·Expert Opinion on Pharmacotherapy·Chi-Un Pae
Dec 6, 2007·Expert Review of Neurotherapeutics·Jeanne Leventhal AlexanderJeffrey J Sherman
Mar 1, 2010·International Journal of Psychiatry in Clinical Practice·Mitsuhiro KamataKoichi Otani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.